ArticleScientific reports2025
Gamma oryzanol modulates hepatic lipids expression and regulates integrated pathways in liver disease pathophysiology under a high sugar fat diet.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Diets high in simple carbohydrates and saturated fats increase the risk of liver diseases. Gamma oryzanol (ORY), a compound found in rice bran, shows promise in addressing metabolic liver diseases, though its impact on lipid pathways requires further exploration. This study evaluated the effects of ORY in rats submitted to a high sugar-fat (HSF) diet using a multiomics approach to unravel its impact on lipid metabolism and associated pathways. Male Wistar rats were fed a control (CTRL), HSF, or HSF + ORY (0.5% w/w) diet for 30 weeks. Hepatic lipid profiling was performed using high-resolution mass spectrometry. Proteins and lipids were integrated into molecular pathway analyses. miR-122 expression was assessed by qRT-PCR, while oxidative stress markers were measured via colorimetric assays. The HSF diet altered 233 lipids compared to CTRL, while ORY supplementation modulated 84 lipids relative to the HSF group, with 39 lipids showing opposing regulatory profiles. Integrating proteomic data revealed key pathways in MAFLD pathophysiology affected by ORY. Additionally, ORY regulated miR-122 expression linked to lipid metabolism and reduced oxidative stress, demonstrating its potential to mitigate HSF-induced liver damage. ORY modulates hepatic lipid profiles and influences integrated metabolic networks, suggesting a significant role in MAFLD prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.